文献速递心脑血管急症

肽酰精氨酸脱亚胺酶2(PAD2)抑制在创伤性脑损伤小鼠模型中与急性和长期获益相关

Peptidyl arginine deiminase 2 (PAD2) inhibition is associated with acute and long-term benefits in a murine model of traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2026-07-02
一句话结论小鼠创伤性脑损伤后5–10分钟给予PAD2选择性抑制剂AFM41a(负荷剂量60 mg/kg、维持剂量30 mg/kg),与病灶缩小及感觉运动、认知功能改善相关。

该研究在控制性皮质撞击诱导的雄性小鼠创伤性脑损伤模型中,于伤后5–10分钟随机给予PAD2选择性抑制剂AFM41a(负荷剂量60 mg/kg溶于DMSO)或溶媒(DMSO),每组6只,伤后1天用尼氏染色评估病灶大小。另一实验中,除负荷剂量外,伤后第2–5天给予维持剂量30 mg/kg AFM41a或溶媒,评估伤后第1–8天神经严重程度评分(NSS)及伤后第21–30天Morris水迷宫(MWM)视空间学习。结果显示AFM41a组病灶显著小于对照组(p<0.05),伤后第1–5天NSS降低(p<0.05),MWM视空间学习与记忆改善(p<0.05)。作者认为PAD2是TBI有前景的治疗靶点,AFM41a作为首个PAD2选择性抑制剂可提供早期神经保护及持续认知获益。

要点

  • 小鼠TBI后5–10分钟给予AFM41a负荷剂量60 mg/kg(溶于DMSO),伤后1天病灶显著小于溶媒对照组(p<0.05)。
  • 另一实验中伤后第2–5天追加维持剂量30 mg/kg AFM41a,伤后第1–5天NSS显著低于对照组(p<0.05),提示感觉运动恢复加快。
  • AFM41a组伤后第21–30天Morris水迷宫视空间学习与记忆表现显著优于对照组(p<0.05)。
  • 作者认为PAD2是TBI有前景的治疗靶点,AFM41a作为首个PAD2选择性抑制剂可提供早期神经保护及持续认知获益。

适用人群与场景

  • 雄性小鼠(c57bl6/j,11–14周龄),控制性皮质撞击诱导的创伤性脑损伤模型。

处置流程与药物剂量

  • 伤后5–10分钟随机给予AFM41a负荷剂量60 mg/kg(溶于DMSO)或溶媒DMSO,每组6只。
  • 另一实验中除负荷剂量外,于伤后第2–5天给予AFM41a维持剂量30 mg/kg或溶媒。

研究设计与关键结果

  • 研究类型为小鼠创伤性脑损伤模型实验;病灶评估实验每组6只,伤后1天尼氏染色显示AFM41a组病灶显著小于对照组(p<0.05)。
  • 另一实验中AFM41a组伤后第1–5天NSS显著低于对照组(p<0.05),提示感觉运动恢复加快。
  • AFM41a组Morris水迷宫(伤后第21–30天)视空间学习与记忆显著优于对照组(p<0.05)。

证据类型、等级与局限

  • 证据类型:小鼠模型实验;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) is a major contributor to trauma-related deaths and disability worldwide. Management of TBI is currently limited to supportive care. We have previously shown that global knockout of PAD2 confers neuroprotection, but its therapeutic potential was unclear. This study was designed to test the hypothesis that selective inhibition of PAD2 following TBI would improve neurological outcomes.

METHODS: Male mice (c57bl6/j, 11-14 wk) were subjected to controlled cortical impact-induced TBI, and 5 to 10 minutes later, randomly given either PAD2 inhibitor ("loading dose" 60 mg/kg AFM41a dissolved in dimethyl sulfoxide (DMSO) or vehicle (DMSO), (n=6/group). One day post-TBI, frozen brain sections were Nissl-stained to determine lesion size. In a separate experiment, the long-term impact of AFM41a treatment on motor, sensory, and cognitive recovery after TBI was evaluated. In addition to the loading dose, animals received a "maintenance dose" of 30 mg/kg of AFM41a or vehicle on postinjury days (PIDs) 2 to 5. Neurologic Severity Scores (NSS on PIDs 1-8) and visuospatial learning via Morris water maze test (MWM on PIDs 21-30) were assessed.

RESULTS: Mice treated with AFM41a had significantly smaller lesion sizes compared with the control group ( p <0.05). Treatment with AFM41a also increased the rate of sensory and motor recovery, as evidenced by reduced NSS on PIDs 1 to 5 ( p <0.05), and improved visuospatial learning and memory as shown by MWM ( p <0.05).

CONCLUSIONS: PAD 2 is a promising therapeutic target in TBI, and its inhibition with AFM41a, a first-in-class PAD2-selective inhibitor, confers early neuroprotection as well as sustained cognitive benefits.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Dawood ZS, Jang A, Mei H, et al. Peptidyl arginine deiminase 2 (PAD2) inhibition is associated with acute and long-term benefits in a murine model of traumatic brain injury. J Trauma Acute Care Surg. 2026. PMID: 42390438. doi:10.1097/TA.0000000000005086

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。